Donanemab introduces a finite-duration treatment model
Donanemab's protocol allows treatment cessation once amyloid plaque clearance is confirmed - a meaningfully different model from indefinite biologic dosing.
Donanemab (Kisunla) was approved with a treatment paradigm distinct from lecanemab: patients can stop infusions once amyloid PET demonstrates plaque clearance below a defined threshold. In trial populations, a substantial proportion reached that threshold within roughly a year.
Three implications are worth watching:
- Patient experience. A defined endpoint changes the conversation about whether to start treatment.
- Health-system planning. Forecasting infusion capacity is harder when treatment duration is variable and patient-specific.
- Long-term durability. What happens after plaque clears - and whether plaque returns over years - remains an open empirical question.
The donanemab model is not necessarily better than lecanemab's continuous dosing; the trade-offs include higher reported ARIA rates and a different infusion schedule. But the option to stop is a structural change in how the field thinks about anti-amyloid therapy.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Key sources
- FDA prescribing information - Kisunla (donanemab)
- TRAILBLAZER-ALZ 2 primary publication and amyloid-clearance subgroup analyses
- Eli Lilly TRAILBLAZER-ALZ program disclosures